Home > Back to Category > Report Information

Pharmaceutical Market Trends, 2010 - 2014

Urch Publishing
October 1, 2010
142 Pages - SKU: URC2852481

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Global

Pharmaceutical Market Trends, 2010 - 2014: Key market forecasts & growth opportunities presents a detailed trend analysis of the global pharmaceutical market to the end of 2009 and forecasts until 2014. This 142 page report, from URCH Publishing, presents a series of market forecasts and growth opportunities in order to help inform pharmaceutical decision-making, particularly in the areas of corporate planning, portfolio management and market forecasting.

The report is divided into five key sections. Chapters 2-5 present historical trends for key pharmaceutical markets, key therapy areas, key products and key companies. The final report chapter outlines future pharmaceutical trends and key growth opportunities.

The data and analysis contained within the report are derived from Delphi Pharma, Company Trends Database to provide a comprehensive, consistent and up-to-date single-point reference for understanding key pharmaceutical market trends in 2010.

“The global pharmaceutical market grew to $808 billion in 2009, at a compound annual growth rate of 9.3% between 1999 and 2009. Year-on-year growth in the global pharmaceutical market decreased to 4.6% in 2009, largely as a result of cost containment in the US and major European markets and the impact of several blockbuster patent expiries in 2008 and 2009.”

Findings from the report include:

125 pharmaceutical drugs generated more than $1billion in global sales. The top 100 blockbuster drugs generated sales of US$285.
The top 10 companies ranked by pharmaceutical sales generated total sales of $317 billion.
The global pharmaceutical market is forecast to grow to $1,033 billion in 2014, an equivalent CAGR of 5.0% over the next five years.
The leading therapy areas by global pharmaceutical sales in 2009 were CNS with a 15.8% market share and cardiovascular with 14.5%.
The CNS pharmaceutical market will decrease from $127.8 billion in 2009 to $118.5 billion in 2014, a CAGR of -1.5%.
In 2009 there were a total of 14 cardiovascular blockbuster products with combined sales amounting to $50.7 billion.
The US pharmaceutical market grew by 3.0% in 2009 to $300.3 billion with highest growth in mail services and clinics.
The major five Germany, France, Italy, Spain and the UK, together accounted for over 60% of all European pharmaceutical sales in 2009.
Pfizer had the greatest number of blockbuster products in 2009 with 14, which includes five inherited through the acquisition of Wyeth.

Additional Information

READERS OF THIS REPORT WILL FIND

Comprehensive guidance on market trends for key countries, regions, therapy areas, products and companies.
Country profiles for leading pharma markets with market segment trends and five year forecasts.
Therapy area profiles for leading classes, Alimentary/metabolism, Antineoplastic/immunomodulatory, Anti-infectives market, CNS, Cardiovascular and Respiratory market with key products and sales forecasts.
Detailed profiles of 10 leading pharmaceutical and biotech products in 2009, including five year future sales forecasts.
Detailed profiles of 10 leading pharmaceutical companies in 2009, including 2014 sales forecasts.(AstraZeneca, Bristol Myers-Squibb, Eli Lilly, GlaxoSmithKline, Johnson and Johnson, Merck & Co, Novartis, Pfizer, Roche, Sanofi-Aventis Wyeth).

Summary
Introduction: Key global markets; Key therapeutic markets; Key products; Key companies; Key trends and opportunities
Chapter 1. Introduction: Global pharmaceutical market; Report overview
Chapter 2. Key global markets: Key pharmaceutical markets; US market leaders; European pharmaceutical market; Japanese pharmaceutical market
Chapter 3. Key therapeutic markets: Key therapy areas; CNS therapy area; Cardiovascular therapy area; Cardiovascular blockbusters; Alimentary/metabolism therapy area; Antineoplastic/immunomodulatory therapy area; Antineoplastic/immunomodulatory blockbusters; Anti-infectives therapy area; Respiratory therapy area
Chapter 4. Key products: Leading products; Blockbuster trends; Blockbusters by drug type; Blockbusters by therapy area; Blockbusters by company
Chapter 5. Key companies: Major pharmaceutical companies; Top 10 pharmaceutical companies; Leading pharmaceutical companies
Chapter 6. Key trends and opportunities: Global market forecasts; Key therapy area forecasts; CNS market; Cardiovascular market; Alimentary/metabolism market; Antineoplastic/immunomodulatory market; Anti-infectives market; Respiratory market; Key product forecasts; Key company forecasts
Appendix: Company Trends Database; Top 125 pharmaceutical products; Top 59 pharmaceutical companies
Figures: Figure 1: Global pharmaceutical market, 1999-2009; Figure 2: Report structure; Figure 3: Global pharmaceutical market share by region, 2009; Figure 4: Global pharmaceutical market by region, 2005-2009; Figure 5: US pharmaceutical market, 2005-2009; Figure 6: US pharmaceutical market share by purchasing channel, 2009; Figure 7: US pharmaceutical market by purchasing channel, 2005-2009; Figure 8: Top 10 products by US pharmaceutical sales, 2009; Figure 9: Top 10 companies by US pharmaceutical sales, 2009; Figure 10: Top 10 companies by share of US pharmaceutical sales, 2009; Figure 11: European pharmaceutical market, 2003-2009; Figure 12: European pharmaceutical market share by country, 2009; Figure 13: European pharmaceutical market by purchasing channel, 2009; Figure 14: Japanese pharmaceutical market, 2003-2009; Figure 15: Global pharmaceutical market by therapy area, 2009; Figure 16: Top 10 product classes by global pharmaceutical sales, 2009; Figure 17: CNS pharmaceutical market, 2005-2009; Figure 18: Cardiovascular pharmaceutical market, 2005-2009; Figure 19: Alimentary/metabolism pharmaceutical market, 2005-2009; Figure 20: Antineoplastic/immunomodulatory pharmaceutical market, 2008-2009; Figure 21: Anti-infectives pharmaceutical market, 2005-2009; Figure 22: Respiratory pharmaceutical market, 2005-2009; Figure 23: Blockbuster drug sales share by drug type, 2009; Figure 24: Blockbuster drug sales share by lifecycle stage, 2009; Figure 25: Blockbuster drug sales share by therapy area, 2009; Figure 26: Blockbuster drug sales share by company, 2009; Figure 27: Major companies pharmaceutical sales, 2007-2009; Figure 28: Major companies revenue share allocation, 2009; Figure 29: Major companies revenue allocation, 2007-2009; Figure 30: Major companies pharmaceutical sales by location, 2009; Figure 31: Top 10 pharma companies pharmaceutical sales, 2007-2009; Figure 32: Top 10 pharma companies by global pharmaceutical sales, 2009; Figure 33: Top 10 biotechnology companies by global revenues, 2009; Figure 34: Top 10 pharma companies revenue share allocation, 2009; Figure 35: Top 10 pharma companies revenue allocation, 2007-2009; Figure 36: Key value drivers for top 10 pharma companies (income), 2009; Figure 37: Key value drivers for top 10 pharma companies (sales), 2009; Figure 38: Key value drivers for top 10 pharma companies (sales/R&D), 2009; Figure 39: Pfizer therapy area sales, 2007-2009; Figure 40: Sanofi-Aventis blockbuster therapy area sales, 2007-2009; Figure 41: Novartis therapy area sales, 2007-2009; Figure 42: GlaxoSmithKline therapy area sales, 2007-2009; Figure 43: Roche therapy area sales, 2007-2009; Figure 44: AstraZeneca therapy area sales, 2007-2009; Figure 45: Merck & Co blockbuster therapy area sales, 2007-2009; Figure 46: Johnson and Johnson blockbuster therapy area sales, 2007-2009; Figure 47: Eli Lilly therapy area sales, 2007-2009; Figure 48: Bristol-Myers Squibb blockbuster therapy area sales, 2007-2009; Figure 49: Global pharmaceutical market forecast, 2005-2014; Figure 50: Global pharmaceutical market forecast by regions, 2005-2014; Figure 51: Top 10 pharmaceutical drugs by forecast sales, 2014; Figure 52: Lipitor (atorvastatin) forecast sales, 2007-2014; Figure 53: Plavix/Iscover (clopidogrel) forecast sales, 2007-2014; Figure 54: Seretide/Advair (fluticasone/salmeterol) forecast sales, 2007-2014; Figure 55: Remicade (infliximab) forecast sales, 2007-2014; Figure 56: Enbrel (etanercept) forecast sales, 2007-2014; Figure 57: Diovan/Co-Diovan (valsartan/hydrochlorothiazide) forecast sales, 2007-2014; Figure 58: Avastin (bevacizumab) forecast sales, 2007-2014; Figure 59: Rituxan/MabThera (rituximab) forecast sales, 2007-2014; Figure 60: Humira (adalimumab) forecast sales, 2007-2014; Figure 61: Seroquel (quetiapine) forecast sales, 2007-2014
Tables: Table 1: Global pharmaceutical market trends by region, 2007-2009; Table 2: US pharmaceutical market trends by purchasing channel, 2007-2009; Table 3: Top 10 products trends by US pharmaceutical sales, 2007-2009; Table 4: Global pharmaceutical market trends by therapy area, 2007-2009; Table 5: Top 10 product classes trends by global pharmaceutical sales, 2007-2009; Table 6: CNS blockbuster drug sales, 2007-2009; Table 7: Cardiovascular blockbuster drug sales, 2005-2009; Table 8: Alimentary/metabolism blockbuster drug sales, 2007-2009; Table 9: Antineoplastic/immunomodulatory blockbuster drug sales, 2007-2009; Table 10: Anti-infectives blockbuster drug sales, 2007-2009; Table 11: Respiratory blockbuster drug sales, 2007-2009; Table 12: Top 20 products by global pharmaceutical sales, 2007-2009; Table 13: Lipitor (atorvastatin) profile, 2009; Table 14: Plavix/Iscover (clopidogrel) profile, 2009; Table 15: Seretide/Advair (fluticasone/salmeterol) profile, 2009; Table 16: Remicade (infliximab) profile, 2009; Table 17: Enbrel (etanercept) profile, 2009; Table 18: Diovan/Co-Diovan (valsartan/hydrochlorothiazide) profile, 2009; Table 19: Avastin (bevacizumab) profile, 2009; Table 20: Rituxan (rituximab) profile, 2009; Table 21: Humira (adalimumab) profile, 2009; Table 22: Seroquel (quetiapine) profile, 2009; Table 23: Top 10 blockbuster products by global pharmaceutical sales growth, 2007-2009; Table 24: Top 10 blockbuster products by declining global pharmaceutical sales, 2007-2009; Table 25: New blockbuster products, 2007-2009; Table 26: Major companies revenue allocation trends, 2007-2009; Table 27: Top 10 pharma companies by global pharmaceutical sales, 2007-2009; Table 28: Top 10 biotechnology companies by global revenues, 2007-2009; Table 29: Top 10 pharma companies revenue allocation trends, 2007-2009; Table 30: Pfizer profile, 2009; Table 31: Pfizer blockbuster sales, 2007-2009; Table 32: Wyeth blockbuster sales, 2007-2009; Table 33: Sanofi-Aventis profile, 2009; Table 34: Sanofi-Aventis blockbuster sales, 2007-2009; Table 35: Novartis profile, 2009; Table 36: Novartis blockbuster sales, 2007-2009; Table 37: GlaxoSmithKline profile, 2009; Table 38: GlaxoSmithKline blockbuster sales, 2007-2009; Table 39: Roche profile, 2009; Table 40: Roche blockbuster sales, 2007-2009; Table 41: Genentech blockbuster sales, 2007-2009; Table 42: AstraZeneca profile, 2009; Table 43: AstraZeneca blockbuster sales, 2007-2009; Table 44: Merck & Co profile, 2009; Table 45: Merck & Co blockbuster sales, 2007-2009; Table 46: Schering-Plough blockbuster sales, 2007-2009; Table 47: Johnson and Johnson profile, 2009; Table 48: Johnson and Johnson blockbuster sales, 2007-2009; Table 49: Eli Lilly profile, 2009; Table 50: Eli Lilly blockbuster sales, 2007-2009; Table 51: Bristol-Myers Squibb profile, 2009; Table 52: Bristol-Myers Squibb blockbuster sales, 2007-2009; Table 53: Global pharmaceutical market forecast by regions, 2005-2014; Table 54: Global pharmaceutical market forecast by therapy area, 2009-2014; Table 55: Top 10 pharmaceutical drugs forecast, 2007-2014; Table 56: Top 10 pharmaceutical companies forecast, 2009-2014; Table 57: Top 125 products by global pharmaceutical sales, 2007-2009; Table 58: Top 59 companies by global pharmaceutical sales, 2007-2009

More Global Prescription Drugs Reports

Global Pharmaceuticals & Medicine Manufacturing by IBISWorld
Global Pharmaceuticals & Medicine Manufacturing This industry comprises companies that manufacture biological, medicinal and pharmaceutical products in various forms including ampoules, tablets, capsules, vials, ointments, powders, ...

Ophthalmic Drugs: World Market Prospects 2012-2022 by Visiongain
How to find trends and revenue predictions for the ophthalmic drug industry What are the commercial prospects for treating eye disorders? Visiongain's report shows you ...

Global Pharmaceutical Survey 2012–2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry by iCD Research
Synopsis This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading pharmaceutical industry executives. The opinions and ...

Global Pharmaceutical Survey 2012–2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry by iCD Research
Synopsis This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading pharmaceutical industry executives. The opinions and ...

World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments) by Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological ...

See all reports like this >>

Pharmaceutical Market Trends, 2010 - 2014

Share this report

Other tasks

Research Assistance

Related Markets

Prescription Drugs Reports

Free Alert Me service